Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effects of Denosumab on the Pharmacokinetics of Etanercept in Postmenopausal Women With Low Mineral Density( BMD) and Rheumatoid Arthritis (RA)

Next Previous
Trial Profile

The Effects of Denosumab on the Pharmacokinetics of Etanercept in Postmenopausal Women With Low Mineral Density( BMD) and Rheumatoid Arthritis (RA)

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Denosumab (Primary) ; Etanercept
  • Indications Postmenopausal osteoporosis; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Amgen

Most Recent Events

  • 08 Mar 2016 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
  • 22 Sep 2015 Planned End Date changed from 1 Sep 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov.
  • 22 Sep 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top